Vertex Pharmaceuticals Performance

VRTX -- USA Stock  

Quarterly Earning Report: October 23, 2019  

Vertex Pharmaceuticals has performance score of 1 on a scale of 0 to 100. The entity has beta of 0.7577 which indicates as returns on market increase, Vertex Pharmaceuticals returns are expected to increase less than the market. However during bear market, the loss on holding Vertex Pharmaceuticals will be expected to be smaller as well. Although it is extremely important to respect Vertex Pharmaceuticals current price movements, it is better to be realistic regarding the information on equity historical returns. The philosophy towards measuring future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By inspecting Vertex Pharmaceuticals technical indicators you can presently evaluate if the expected return of 0.0465% will be sustainable into the future. Vertex Pharmaceuticals right now has a risk of 1.7361%. Please validate Vertex Pharmaceuticals Value At Risk as well as the relationship between Semi Variance and Kurtosis to decide if Vertex Pharmaceuticals will be following its existing price patterns.

Risk-Adjusted Performance

Compared to the overall equity markets, risk-adjusted returns on investments in Vertex Pharmaceuticals Incorpor are ranked lower than 1 (%) of all global equities and portfolios over the last 30 days. Inspite fairly strong basic indicators, Vertex Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Quick Ratio3.51
Fifty Two Week Low151.80
Target High Price254.00
Fifty Two Week High195.81
Target Low Price183.00
Horizon     30 Days    Login   to change

Vertex Pharmaceuticals Relative Risk vs. Return Landscape

If you would invest  17,413  in Vertex Pharmaceuticals Incorpor on September 17, 2019 and sell it today you would earn a total of  359.00  from holding Vertex Pharmaceuticals Incorpor or generate 2.06% return on investment over 30 days. Vertex Pharmaceuticals Incorpor is currently generating 0.0465% of daily expected returns and assumes 1.7361% risk (volatility on return distribution) over the 30 days horizon. In different words, 15% of equities are less volatile than Vertex Pharmaceuticals and 99% of traded equity instruments are projected to make higher returns than the company over the 30 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 30 days, Vertex Pharmaceuticals is expected to generate 1.76 times more return on investment than the market. However, the company is 1.76 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The DOW is currently generating roughly 0.0 per unit of risk.

Vertex Pharmaceuticals Market Risk Analysis

Sharpe Ratio = 0.0268
Good Returns
Average Returns
Small Returns
Negative ReturnsVRTX

Vertex Pharmaceuticals Relative Performance Indicators

Estimated Market Risk
  actual daily
 15 %
of total potential
Expected Return
  actual daily
 0 %
of total potential
Risk-Adjusted Return
  actual daily
 1 %
of total potential
Based on monthly moving average Vertex Pharmaceuticals is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Vertex Pharmaceuticals by adding it to a well-diversified portfolio.

Vertex Pharmaceuticals Alerts

Equity Alerts and Improvement Suggestions

Over 97.0% of the company outstanding shares are owned by institutional investors
Latest headline from MacroaxisInsider: Exercise or conversion by Boger Kenneth S of 12000 shares of Vertex Pharmaceuticals subject to Rule 16b-3
Also please take a look at World Market Map. Please also try Crypto Portfolio Optimizer module to optimize portfolio of digital coins and token across multiple currency and exchanges.